

Search

Subject Guide

Journals

Books

Services

Resources

Login/Admin

Logout

Sitemap

Help

Contacts

Vol. 5, No. 1, 2012

Article (PDF 568 KB)

Open Access

Published: March 2012

Successful Treatment of Advanced Metastatic Prostate Cancer following Chemotherapy Based on Molecular Profiling

Charles E. Myers^a, Gargi Basu^b, Brian Wright^b, Joanne Mahanes^a, Anthony Spinelli^c^aFoundation for Cancer Research and Education, Earlysville, Va.,^bCaris Life Sciences, Phoenix, Ariz., and^cDepartment of Interventional Radiology, Martha Jefferson Hospital, Charlottesville, Va., USA

Address of Corresponding Author

Case Rep Oncol 2012;5:154-158 (DOI: 10.1159/000338077)

Key Words

- Prostate
- Molecular profiling
- Post-chemotherapy response

Abstract

After Taxotere fails, treatment options for metastatic prostate cancer are limited. The three drugs with FDA approval in this setting, Jevtana, Provenge and Zytiga, are associated with median survivals of less than 2 years. In part, the impact on survival is the result of low response rates, indicating a significant proportion of patients exhibiting de novo resistance to these agents. An alternate approach is to let treatment selection be governed by gene expression profiling so that the treatment is tailored to the specific patient. Here, we report a case of metastatic prostate cancer with a dramatic response to treatment selected based on molecular profiling. This patient had failed LHRH agonist, bicalutamide, Taxotere, and doxorubicin. Molecular profiling showed overexpression of the androgen receptor and he had a dramatic response of measurable disease to second-line hormonal therapy with ketoconazole, estrogen and Leukine.

Copyright © 2012 S. Karger AG, Basel

Author Contacts

Charles E. Myers
Foundation for Cancer Research and Education 690 Bent Oaks Drive
Earlysville, VA 22936 (USA)
Tel. +1 434 220 4539, E-Mail jm.fcrc@earthlink.net

Article Information

Published online: March 29, 2012
Number of Print Pages : 5
Number of Figures : 1,

Journal Home

Journal Content

Guidelines

Editorial Board

Aims and Scope

Download Citation

Cited in Web of Science®

Recommend this



Published online
within 2 weeks of
acceptance

CARIS TARGET NOW
EVIDENCE-BASED MOLECULAR PROFILING SERVICE



For non-native English speakers and international authors who would like assistance with their writing before submission, we suggest *American Journal Experts* for their [scientific editing](#) service.

Content Ed Net
INTERNATIONAL MEDICAL JOURNAL SOLUTIONS

日本からのご投稿者様へ:

Case Reports シリーズ
原稿執筆・ネイティブチェック等
のテクニカルサポートには
Content'Ed Net, Inc. の
メディカルライティングサービス
ご利用を推奨いたします。
www.contentednet.com
tel. 06-6445-1301
e mail info@contentednet.co.jp

■ Copyright © 2012 S. Karger AG, Basel